Skip to main content

Table 6 Adverse events

From: Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial

Events Arm 1:
HCQ + SOC
Arm 2:
SOC
Number randomized 55 50
Participants who had any adverse event (AE), n (%)a 33 (60) 27 (54.0)
Participants who had any severe adverse event (SAE), n (%)a 0 0
Participants who had any grade 3 or 4 adverse events, n (%)b 2 (6.1) 3 (11.1)
Number of grade 3 or 4 AEs 2 3
 Grade 3 or 4 adverse events listing, number   
  Elevated QTc (> 450 males, > 470 females) 1 3
  Painful eye after HCQ dosages 1 0
Grade 3 or 4 relationship with study drug, number   
 Definitec 1 N/A
 Probable 0 N/A
 Possible 0 N/A
 Unlikely 0 N/A
 Unrelated 1 N/A
  1. aPercent of total participants randomized
  2. bPercent of those who had any AE
  3. cDefinite related to study drugs was elevated QTc